S&P 500   4,243.08 (+0.78%)
DOW   33,581.80 (+0.82%)
QQQ   327.79 (+0.57%)
AAPL   169.91 (+0.40%)
MSFT   289.03 (-0.04%)
META   180.64 (+1.29%)
GOOGL   120.89 (+0.99%)
AMZN   143.38 (+0.48%)
TSLA   886.34 (+0.37%)
NVDA   180.63 (-0.19%)
NIO   20.97 (+4.59%)
BABA   95.44 (+3.26%)
AMD   99.56 (+0.51%)
MU   62.27 (+1.42%)
T   18.03 (+0.11%)
CGC   3.38 (+2.74%)
GE   78.13 (+1.28%)
F   15.73 (+1.48%)
DIS   123.00 (+9.40%)
AMC   24.50 (+3.51%)
PYPL   101.08 (+2.19%)
PFE   48.52 (-2.86%)
NFLX   249.50 (+2.21%)
S&P 500   4,243.08 (+0.78%)
DOW   33,581.80 (+0.82%)
QQQ   327.79 (+0.57%)
AAPL   169.91 (+0.40%)
MSFT   289.03 (-0.04%)
META   180.64 (+1.29%)
GOOGL   120.89 (+0.99%)
AMZN   143.38 (+0.48%)
TSLA   886.34 (+0.37%)
NVDA   180.63 (-0.19%)
NIO   20.97 (+4.59%)
BABA   95.44 (+3.26%)
AMD   99.56 (+0.51%)
MU   62.27 (+1.42%)
T   18.03 (+0.11%)
CGC   3.38 (+2.74%)
GE   78.13 (+1.28%)
F   15.73 (+1.48%)
DIS   123.00 (+9.40%)
AMC   24.50 (+3.51%)
PYPL   101.08 (+2.19%)
PFE   48.52 (-2.86%)
NFLX   249.50 (+2.21%)
S&P 500   4,243.08 (+0.78%)
DOW   33,581.80 (+0.82%)
QQQ   327.79 (+0.57%)
AAPL   169.91 (+0.40%)
MSFT   289.03 (-0.04%)
META   180.64 (+1.29%)
GOOGL   120.89 (+0.99%)
AMZN   143.38 (+0.48%)
TSLA   886.34 (+0.37%)
NVDA   180.63 (-0.19%)
NIO   20.97 (+4.59%)
BABA   95.44 (+3.26%)
AMD   99.56 (+0.51%)
MU   62.27 (+1.42%)
T   18.03 (+0.11%)
CGC   3.38 (+2.74%)
GE   78.13 (+1.28%)
F   15.73 (+1.48%)
DIS   123.00 (+9.40%)
AMC   24.50 (+3.51%)
PYPL   101.08 (+2.19%)
PFE   48.52 (-2.86%)
NFLX   249.50 (+2.21%)
S&P 500   4,243.08 (+0.78%)
DOW   33,581.80 (+0.82%)
QQQ   327.79 (+0.57%)
AAPL   169.91 (+0.40%)
MSFT   289.03 (-0.04%)
META   180.64 (+1.29%)
GOOGL   120.89 (+0.99%)
AMZN   143.38 (+0.48%)
TSLA   886.34 (+0.37%)
NVDA   180.63 (-0.19%)
NIO   20.97 (+4.59%)
BABA   95.44 (+3.26%)
AMD   99.56 (+0.51%)
MU   62.27 (+1.42%)
T   18.03 (+0.11%)
CGC   3.38 (+2.74%)
GE   78.13 (+1.28%)
F   15.73 (+1.48%)
DIS   123.00 (+9.40%)
AMC   24.50 (+3.51%)
PYPL   101.08 (+2.19%)
PFE   48.52 (-2.86%)
NFLX   249.50 (+2.21%)
NASDAQ:EYES

Second Sight Medical Products - EYES Stock Forecast, Price & News

$2.05
+0.09 (+4.59%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.97
$2.07
50-Day Range
$1.80
$2.57
52-Week Range
$1.14
$4.24
Volume
63,670 shs
Average Volume
230,575 shs
Market Capitalization
$80.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
EYES stock logo

About Second Sight Medical Products (NASDAQ:EYES) Stock

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.

Second Sight Medical Products Trading Up 4.6 %

Shares of EYES Stock opened at $2.05 on Thursday. Second Sight Medical Products has a 52 week low of $1.14 and a 52 week high of $4.24. The company's fifty day simple moving average is $2.11 and its two-hundred day simple moving average is $1.69.

Insider Activity

In other news, Director Gregg Williams purchased 387,044 shares of the business's stock in a transaction that occurred on Wednesday, May 18th. The shares were bought at an average cost of $1.66 per share, for a total transaction of $642,493.04. Following the acquisition, the director now owns 10,277,853 shares of the company's stock, valued at approximately $17,061,235.98. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have acquired 636,734 shares of company stock worth $1,163,387. 47.20% of the stock is currently owned by corporate insiders.

Receive EYES Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Second Sight Medical Products and its competitors with MarketBeat's FREE daily newsletter.

EYES Stock News Headlines

EYES Stock Pops on Biotech Merger Plans. 5 Things to Know.
See More Headlines
Receive EYES Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Second Sight Medical Products and its competitors with MarketBeat's FREE daily newsletter.

EYES Company Calendar

Last Earnings
6/29/2020
Today
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EYES
Employees
15
Year Founded
N/A

Profitability

Net Income
$-8,920,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.38 million
Book Value
$1.73 per share

Miscellaneous

Free Float
20,808,000
Market Cap
$80.79 million
Optionable
Optionable
Beta
2.55

Key Executives

  • Mr. Scott Dunbar (Age 64)
    Acting Chief Exec. Officer
    Comp: $301.39k
  • Mr. Edward Jonathon Sedo (Age 66)
    Acting Chief Accounting Officer, Principal Financial Officer & Controller
    Comp: $199.18k
  • Mr. Edward David Randolph (Age 64)
    Chief Operating Officer
    Comp: $366.44k
  • Dr. Jessy Dana Dorn Ph.D. (Age 46)
    VP of Clinical & Scientific Affairs
    Comp: $282.7k
  • Gunnar Bjorg
    Founder
  • Ms. Lisa M. Wilson (Age 57)
    Founder & Pres of In-Site Communications and Investor Relations for Second Sight













EYES Stock - Frequently Asked Questions

How have EYES shares performed in 2022?

Second Sight Medical Products' stock was trading at $1.63 at the beginning of the year. Since then, EYES stock has increased by 25.8% and is now trading at $2.05.
View the best growth stocks for 2022 here
.

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products, Inc. (NASDAQ:EYES) announced its quarterly earnings data on Monday, June, 29th. The medical device company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by $0.16.

What is Will McGuire's approval rating as Second Sight Medical Products' CEO?

5 employees have rated Second Sight Medical Products Chief Executive Officer Will McGuire on Glassdoor.com. Will McGuire has an approval rating of 57% among the company's employees. This puts Will McGuire in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Second Sight Medical Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), VBI Vaccines (VBIV), Shopify (SHOP), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Ekso Bionics (EKSO) and OPKO Health (OPK).

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an initial public offering on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

What is Second Sight Medical Products' stock symbol?

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

How do I buy shares of Second Sight Medical Products?

Shares of EYES stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Second Sight Medical Products' stock price today?

One share of EYES stock can currently be purchased for approximately $2.05.

How much money does Second Sight Medical Products make?

Second Sight Medical Products (NASDAQ:EYES) has a market capitalization of $80.79 million and generates $3.38 million in revenue each year.

How can I contact Second Sight Medical Products?

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The official website for the company is www.secondsight.com. The medical device company can be reached via phone at (818) 833-5000, via email at investors@secondsight.com, or via fax at 818-833-5067.

This page (NASDAQ:EYES) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.